Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Sparine
Synonyms :
promazine
Class :
Phenothiazine antipsychotics
Brand Name :
Sparine
Synonyms :
promazine
Class :
Phenothiazine antipsychotics
Dosage forms and strengths Â
Intramuscular; intravenous liquid Â
25 mg/mlÂ
50 mg/mlÂ
Tablet Â
50 mgÂ
25 mg Â
Dosage forms and strengths Â
Intramuscular; intravenous liquid Â
25 mg/mlÂ
50 mg/mlÂ
Tablet Â
50 mgÂ
25 mg Â
For the age of the child is more than twelve years
Oral/Intramuscular- Administer 10 to 25 mg six times & four times a day
Refer adult dosingÂ
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased effect of a CNS depressant when combined with cannabinoid products
may have an increased effect of a CNS depressant when combined with cannabinoid products
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
promazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may increase the CNS depressant of opioid agonists
may have an increased CNS depressant effect when combined with flunitrazepam
may have an increased CNS depressant effect when combined with flunitrazepam
may have an increased CNS depressive effect when combined with suvorexant
may have an increased CNS depressant effect when combined with buprenorphine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with zolpidem
may decrease the therapeutic effect of anti-Parkinson agents
may have an increased CNS depressant effect when combined with dexmedetomidine
may have an increased Effect of a CNS depressant when combined with oxycodone
dexmedetomidine: they may increase the CNS depressant effect of CNS Depressants
ropeginterferon alfa 2b: they may increase the CNS depressant effect of CNS Depressants
obinutuzumab: they may increase the CNS depressant effect of CNS Depressants
cimetropium: they may increase the CNS depressant effect of CNS Depressants
guanethidine: they may increase the CNS depressant effect of CNS Depressants
potassium phosphate: they may increase the CNS depressant effect of CNS Depressants
nitroglycerin: they may increase the CNS depressant effect of CNS Depressants
cocaine: they may increase the CNS depressant effect of CNS Depressants
rimonabant has the potential to intensify the effects of additional central nervous system depressants, including alcohol, benzodiazepines, and opioids, resulting in heightened sedation or respiratory depression
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may increase the QTc-prolonging effect of thiazide diuretics
may increase the QTc-prolonging effect of thiazide diuretics
may increase the QTc-prolonging effect of thiazide diuretics
may increase the QTc-prolonging effect of thiazide diuretics
thiazide and it’s like diuretics increase the effect of QTc prolongation
thiazide and it’s like diuretics increase the effect of QTc prolongation
thiazide and it’s like diuretics increase the effect of QTc prolongation
thiazide and it’s like diuretics increase the effect of QTc prolongation
thiazide and it’s like diuretics increase the effect of QTc prolongation
The use of Loop diuretics may increase the QTc-prolonging influence of promazine
The use of Loop diuretics may increase the QTc-prolonging influence of promazine
The use of Loop diuretics may increase the QTc-prolonging influence of promazine
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
azelastine may enhance the CNS depressant effect of CNS Depressants
glycopyrrolate inhaled and formoterolÂ
may increase the QTc interval when combined
it increases the efficacy of CNS depressants
may have an increased CNS depressant effect when combined with flunarizine
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
CNS depressants increase the efficacy of thalidomide
may have an increased CNS depressant effect when combined with CNS depressants
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increased CNS depressant effect when combined with orphenadrine
may have an increased CNS depressant effect when combined with paraldehyde
bromperidol: they may increase the CNS depressant effect of CNS Depressants
antipsychotic agents increase the effect of arrhythmia of saquinavir
Could potentially reduce the therapeutic efficacy of antipsychotic agents
The potential for increased toxicity of Sulpiride could be amplified by the presence of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
revefenacin: they may increase the CNS depressant effect of CNS Depressants
betahistine: they may increase the CNS depressant effect of CNS Depressants
doxofylline: they may increase the CNS depressant effect of CNS Depressants
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
could increase the vasopressor action
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
promazine: they may increase the myelosuppressive effect of myelosuppressive agents
it may diminish the metabolism when combined with diosmin
may have an increased CNS depressant effect when combined with alcohol
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased CNS depressant effect when combined with alcohol
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the myelosuppressive effect
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
may enhance adverse myelosuppressive effects
may enhance adverse myelosuppressive effects
may enhance adverse myelosuppressive effects
may enhance adverse myelosuppressive effects
may enhance the risk of myelosuppression
may enhance the adverse effects such as bone marrow suppression
when both drugs are combined, there may be an increase in the risk of the myelosuppressive effect of myelosuppressive agents 
it may increase the bone marrow suppression effects of promazine
they enhance the effect of myelosuppression in myelosuppressive agents
it increases the effect of myelosuppression in myelosuppressive agents
may enhance the adverse effects such as bone marrow suppression
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
it increases the effect of CNS depressants
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
CNS depressants increase the effect of sedation of pramipexole
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids reduce the systemic absorption of phenothiazine derivatives
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the CNS depressant effect
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the CNS depressant effect
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may increase the hypotensive effect of antihypertensives
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may increase the hypotensive effect of blood pressure-lowering agents
moexipril/hydrochlorothiazideÂ
may increase the QTc prolonging effect of thiazide and thiazide like diuretics
may have an increased CNS depressive effect of CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
it increases the toxicity of CNS depressants
it increases the effect of CNS depressants
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased CNS depressant effect when combined with cannabinoid-containing products
may have an increased CNS depressant effect when combined with cannabinoid-containing products
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may increase the toxic effect of CNS depressants
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the toxic effect of CNS depressants
may increase the risk of adverse effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased CNS depressant effect when combined with brexanolone
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with dexmethylphenidate
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
metoclopramide: they may increase the CNS depressant effect of CNS Depressants
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the serotonergic effects
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the myelosuppressive effect of Myelosuppressive Agents
they increase the effect of sedation of ropinirole
may have an increased hypotensive effect when combined with antipsychotic agents
metyrosine: they may increase the sedative effect of CNS Depressants
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
The Therapeutic efficacy of quinagolide might be reduced
may enhance the QTc-prolonging effect of each other when combined
The sedative effect of rotigotine might be intensified by the presence of CNS Depressants
Could potentially amplify the toxicity of antipsychotic agents
perampanel: they may increase the CNS depressant effect of CNS Depressants
ozanimod: they may increase the CNS depressant effect of CNS Depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
valerian: they may increase the CNS depressant effect of CNS Depressants
lithium: they may increase the neurotoxic effect of antipsychotic agents
When abrocitinib is used together with promazine, this leads to a reduction in abrocitinib metabolism
When acenocoumarol is used together with promazine, this leads to a reduction in abrocitinib metabolism
When acetaminophen is used together with promazine, this leads to a reduction in acetaminophen metabolism
When acyclovir is used together with promazine, this leads to a reduction in acyclovir metabolism
When alogliptin is used together with promazine, this leads to a reduction in alogliptin metabolism
When aminophenazone is used together with promazine, this leads to a reduction in aminophenazone metabolism
When aminophylline is used together with promazine, this leads to a reduction in aminophylline metabolism
When antipyrine is used together with promazine, this leads to a reduction in antipyrine metabolism
mianserin: they may decrease the therapeutic effect of antipsychotics
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
lutropin alfa: they may increase the CNS depressant effect of CNS Depressants
solriamfetol: they may increase the CNS depressant effect of CNS Depressants
aminolevulinic acid: they may increase the CNS depressant effect of CNS Depressants
sparsentan: they may increase the CNS depressant effect of CNS Depressants
indoramin: they may increase the CNS depressant effect of CNS Depressants
lithium: they may increase the CNS depressant effect of CNS Depressants
methylphenidate: they may increase the CNS depressant effect of CNS Depressants
aldesleukin: it may decrease the excretion rate of abacavir CNS depressant
acetazolamide: it may increase the risk or severity of CNS depression
aceclofenac: it may increase the risk or severity of CNS depression
acebutolol: it may increase the risk or severity of CNS depression
balsalazide: it may increase the risk or severity of CNS depression
mepyramine: it may increase the risk or severity of CNS depression
acrivastine: it may increase the risk or severity of CNS depression
alfentanil: it may increase the risk or severity of CNS depression
baricitinib: it may increase the risk or severity of CNS depression
baclofen: it may increase the risk or severity of CNS depression
carbidopa: it may increase the risk or severity of CNS depression
dabrafenib: it may increase the risk or severity of CNS depression
dapagliflozin: it may increase the risk or severity of CNS depression
amantadine: it may increase the risk or severity of CNS depression
benzphetamine: it may increase the risk or severity of CNS depression
anagrelide: it may increase the risk or severity of CNS depression
benzyl alcohol: it may increase the risk or severity of CNS depression
mianserin: it may increase the risk or severity of CNS depression
may have an increased neurotoxic effect when combined with antipsychotic agents
anakinra: it may decreased the serum concentration of CNS depressants
bortezomib: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the metabolism of CNS depressants
carvedilol: it may increase the metabolism of CNS depressants
may increase the CNS depressant effect of CNS depressants
When promazine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
CNS depressants increase the effect of zolpidem
it increases the effect of CNS depressants
Actions and Spectrum:Â
Action:Â
Antipsychotic: promazine primarily exerts its therapeutic effect as an antipsychotic. It acts by blocking certain receptors in the brain, particularly dopamine receptors. This antagonism of dopamine receptors helps to reduce the positive symptoms of psychotic disorders such as hallucinations, delusions, and thought disorders.Â
Spectrum:Â
Schizophrenia: promazine is used to treat schizophrenia and related psychotic disorders. It can help manage the positive symptoms of the illness, such as hallucinations and delusions.Â
Acute Psychotic Episodes: promazine is sometimes used in emergency settings to manage acute episodes of psychosis, helping to calm individuals who are severely agitated or hallucinating.Â
Â
Frequency not defined Â
DizzinessÂ
NightmaresÂ
Blurred visionÂ
DrowsinessÂ
Dry mouthÂ
Black Box Warning:Â Â
None
Contraindication/Caution:Â Â
Hypersensitivity: promazine should not be used in individuals who have a known hypersensitivity or allergy to the drug or its components.Â
Severe Central Nervous System Depression: It should be avoided in patients with severe depression of the central nervous system, including those with alcohol or drug intoxication.Â
Blood Dyscrasias: promazine is contraindicated in patients with a history of blood dyscrasias, such as agranulocytosis, which this medication can exacerbate.Â
Liver Disease: Individuals with severe liver disease or hepatic impairment should avoid promazine, as the drug is metabolized in the liver, and impaired liver function can lead to elevated levels of the drug in the bloodstream.Â
Bone Marrow Depression: promazine should not be used in individuals with bone marrow depression or other hematologic disorders.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: promazine is a first-generation antipsychotic medication that is primarily used to manage symptoms of various psychiatric disorders, such as schizophrenia and severe agitation.Â
Pharmacodynamics:Â Â
Dopamine Receptor Antagonism: promazine mainly achieves its therapeutic benefits by inhibiting dopamine receptors in the brain. It is a non-selective antagonist for dopamine receptors, particularly D2 receptors. By antagonizing these receptors, promazine helps reduce the overactivity of dopamine, which is associated with symptoms of psychosis.Â
Serotonin Receptor Antagonism: In addition to dopamine receptors, promazine also blocks serotonin receptors, particularly 5-HT2A receptors. This dual receptor antagonism can help improve mood and alleviate some of the negative symptoms of schizophrenia. Â
Pharmacokinetics:Â
AbsorptionÂ
promazine is well absorbed when taken orally, but its absorption can be slowed when taken with food. It is also available in injectable forms for rapid onset of action.Â
DistributionÂ
promazine has a relatively large distribution volume, which is distributed throughout the body. It can cross the blood-brain barrier, thus enabling its impact on the central nervous system.Â
MetabolismÂ
promazine is extensively metabolized in the liver, primarily through oxidation and conjugation processes. Â
Excretion and EliminationÂ
The elimination half-life of promazine can vary between individuals but is generally around 12 to 36 hours. It is primarily excreted through urine.Â
Administration: Â
The healthcare provider will establish the proper promazine dosage after considering factors such as the patient’s medical condition, age, weight, and their response to the medication.Â
Patient information leafletÂ
Generic Name: promazineÂ
Why do we use promazine? Â
promazine is often prescribed to manage symptoms of psychosis, including hallucinations, delusions, and thought disorders. It can be beneficial for individuals with schizophrenia or other psychotic disorders. promazine can be used with other psychiatric medications to enhance their effectiveness or address specific symptoms.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
